LXRX — Lexicon Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $662.98m
- $523.81m
- $49.80m
Brief: Lexicon Pharmaceuticals Announces Successful End-Of-Phase 2 Meeting With FDA For Pilavapadin In The Treatment Of Diabetic Peripheral Neuropathic Pain
Brief: Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference
Brief: Clinical Data On Effect Of Sotagliflozin On Adipose Distribution In Non-Diabetic Patients
Brief: Lexicon Pharmaceuticals Inc Files For Offering Of Up To $75 Million Of Common Stock - SEC Filing
Lexicon Pharma Q3 net loss narrows as R&D costs drops
Brief: Lexicon Pharmaceuticals Announces Update On Submission Of Additional Data To U.S. FDA
Lexicon expects delay in FDA feedback on additional data for its diabetes drug (updated)
Lexicon submits additional data for its diabetes drug to US FDA
Brief: Lexicon Submits New Data to FDA Supporting Zynquista’s Use in Type 1 Diabetes
Lexicon Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Lexicon Pharmaceuticals Q2 Product Revenue USD 1.322 Million
Lexicon Pharmaceuticals Inc expected to post a loss of 8 cents a share - Earnings Preview
Brief: Lexicon Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement
Lexicon Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Lexicon Pharmaceuticals Q1 Operating Income USD -25.679 Million
Lexicon Pharmaceuticals Inc expected to post a loss of 10 cents a share - Earnings Preview
Lexicon Pharmaceuticals Inc expected to post a loss of 10 cents a share - Earnings Preview
Lexicon surges on licensing deal with Novo Nordisk for obesity drug
Brief: Lexicon Pharmaceuticals Announces Exclusive License Agreement With Novo Nordisk For LX9851